CG Oncology (CGON) Stock Forecast, Price Target & Predictions
CGON Stock Forecast
CG Oncology stock forecast is as follows: an average price target of $62.33 (represents a 116.46% upside from CGON’s last price of $28.80) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
CGON Price Target
The average price target for CG Oncology (CGON) is $62.33 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $75.00 to $52.00. This represents a potential 116.46% upside from CGON's last price of $28.80.
CGON Analyst Ratings
According to 7 Wall Street analysts, CG Oncology's rating consensus is 'Buy'. The analyst rating breakdown for CGON stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
CG Oncology Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 24, 2024 | David Dai | UBS | $60.00 | $35.61 | 68.49% | 108.37% |
| Sep 17, 2024 | Andres Maldonado | H.C. Wainwright | $75.00 | $37.94 | 97.68% | 160.46% |
| Sep 16, 2024 | Corinne Johnson | Goldman Sachs | $52.00 | $34.80 | 49.43% | 80.59% |
| May 13, 2024 | Corinne Johnson | Goldman Sachs | $50.00 | $25.84 | 93.50% | 73.64% |
The latest CG Oncology stock forecast, released on Oct 24, 2024 by David Dai from UBS, set a price target of $60.00, which represents a 68.49% increase from the stock price at the time of the forecast ($35.61), and a 108.37% increase from CGON last price ($28.80).
CG Oncology Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 4 |
| Avg Price Target | - | $60.00 | $59.25 |
| Last Closing Price | $28.80 | $28.80 | $28.80 |
| Upside/Downside | -100.00% | 108.37% | 105.76% |
In the current month, the average price target of CG Oncology stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to CG Oncology's last price of $28.80. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 24, 2024 | UBS | Buy | Initialise | |
| Oct 21, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Sep 23, 2024 | RBC Capital | Outperform | Initialise | |
| Sep 17, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 16, 2024 | Johnson Rice | Buy | Buy | Hold |
| Sep 16, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Jun 28, 2024 | Johnson Rice | Buy | Buy | Hold |
| Jun 28, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Jun 28, 2024 | Bank of America Securities | Buy | Initialise | |
| May 14, 2024 | Morgan Stanley | Buy | Buy | Hold |
| May 13, 2024 | Goldman Sachs | Buy | Upgrade |
CG Oncology's last stock rating was published by UBS on Oct 24, 2024. The company Initialise its CGON rating from "null" to "Buy".
CG Oncology Financial Forecast
CG Oncology Revenue Forecast
| Revenue |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| # Analysts |
| Surprise % |
CG Oncology's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. CGON's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
CG Oncology EBITDA Forecast
| # Analysts |
| EBITDA |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
undefined analysts predict CGON's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than CG Oncology's previous annual EBITDA (undefined) of $NaN.
CG Oncology Net Income Forecast
| # Analysts |
| Net Income |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
CG Oncology's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CGON's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
CG Oncology SG&A Forecast
| # Analysts |
| SG&A |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
CG Oncology's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to CGON last annual SG&A of $NaN (undefined).
CG Oncology EPS Forecast
| # Analysts |
| EPS |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
According to undefined Wall Street analysts, CG Oncology's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CGON previous annual EPS of $NaN (undefined).